Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions
- blonca9
- 5 hours ago
- 1 min read
He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.
Brought to you by









.png)




